Profile specialty versus general practice reps Percentage of time reps can adequately detail or sell to physicians
What is the long-term forecast for such a crowded selling field? At best, it begs comparison to Garrett Hardin's "Tragedy
of the Commons." This concept was popularized in 1968 when Hardin used it to illustrate the effect of human population growth
and unregulated use of natural resources. It is the "tragic" social phenomenon of people acting to obtain short-term individual
gains, which in the long run leads to a loss for the group as a whole.
Most significant reason for lack of time reps have available to detail MDs
Among the best-known real-world examples for this dynamic is the destruction of pasture lands due to overgrazing by too many
cattle. The premise is that if a pasture is shared by local herders and every herder is interested in maximizing his yield,
each will increase his herd size whenever possible. But there's both a positive and negative consequence for each addition.
On the one hand, the guy who expands his herd receives a higher payout. But the field becomes increasingly degraded with each
addition, and — ultimately — even the ambitious herder will reap diminishing returns as time goes by.
The costs and benefits of such decisions are unequally shared: The individual herder gains all of the advantages of additional
animals, but all who use the pasture are burdened with the disadvantages. So when an individual herder weighs his options,
the rational course of action is to add to the herd — as often as possible. And since this is the optimal course for all the
herders, overgrazing and degradation of the pasture is the near-sure outcome.
This metaphor describes how overuse of a limited resource ultimately dooms the resource for everyone.
Sizing a sales force: The dilemma
Prediction of company's (for reps) and district's (for managers) overall sales force size (in terms of number of reps) by
2009
No one's trying to ruin the field or doom the resource; decision-makers are simply making sound business decisions — in the context of competitor
actions. It's the age-old conflict between individual interests and the common good. A game theory known as Prisoner's Dilemma
helps explain the decision-making process of this social reality.
Using the pharma sales model as an analogy, the "too many sales reps" problem could theoretically be addressed if every pharma
and biotech company reduced its sales force. However, if one company chose not to play along, then it would likely win greater
access to physicians because the selling field would suddenly be less crowded with competitors.
This means that the smartest business decision is to defect, to not go along with the reduction. It's the only viable way
to get ahead. So the concept of the "defector" — a term used to describe one who pursues individual gain in the Prisoner's
Dilemma game theory — is very relevant to the pharma sales-model issue.
Gary Schwebach, PhD, cofounded G & S Research Inc. in 1997. He is a principal and president of the company, currently responsible for corporate governance. His professional expertise is in business and marketing strategy and research methodologies. Before establishing G & S Research, Dr. Schwebach was a market research and strategy consultant to Eli Lilly and Company. With a doctorate and masters degree in business administration from Indiana University, Dr. Schwebach taught marketing strategy and market research at Indiana at gschwebach@gs-research.com.
Articles by Gary Schwebach
Stephanie Cohen
Stephanie Cohen is the senior methodol- ogist at G & S Research Inc., where she is responsible for developing research methodologies and analytical plans that fully address the business decisions of the firm's pharmaceutical and biotech clients. She also oversees analytical work and conducts internal training. Cohen has extensive experience in pharmaceutical market research, marketing, and brand strategy development at all stages of the product life cycle. Her background includes leadership positions at Amgen and SmithKline Beecham (now GlaxoSmithKline), and strategy consulting experience at Corporate Decisions Inc.
Articles by Stephanie Cohen
Matthew Herman
editor-in-chief
Matthew Herman is the editor-in-chief of Pharmaceutical Representative magazine.
Articles by Matthew Herman
ADVERTISEMENT
Survey
The more people talk about healthcare reform the less consensus there is, what do you think of current efforts to reform the system?
Healthcare reform is
Good for pharma
18%
Bad for pharma
37%
Doomed to failure
24%
An idea whose time has come
21%
GOOGLE ADVERTISEMENTS
Source: Pharmaceutical Representative,
11/1/2007 Click here